Clinical Trials Browser

Neoplasm Metastasis × Erlotinib Hydrochloride × 30 days × Clear all

NCT04449874 2026-06-02

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Phase 1 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms